Fig. 5
From: Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
The multi-omics research mode for CAR T-cell therapy. (A) In the multi-omics research mode, a large clinical cohort with complete clinical information as well as biological samples and single-cell multi-omics technologies would be combined to create multi-level metadata from micro to macros, which provides guidance for the development of precision medicine. In the field of CAR T-cell therapy, integration of multi-dimensional omics data promotes a comprehensive description of the molecular regulatory network during CAR T-cell functional processes, leading to the discovery of new mechanisms and targeted treatment strategies for CAR T-cell therapy and thus bringing more insights into this field at both the basic and clinical levels. (B) Basic research is dedicated to illustrating the basic biological characteristics of CAR T-cells, including the effect of each manufacturing stage on the final cellular products, the heterogeneity in the evolution of functional phenotypes during the CAR T-cell functional process, the interaction between CAR T-cells and various cells within the TME and the selection of suitable target antigens, which will advance the safety and efficacy of CAR T-cell therapy. (C) Clinical question-driven research focus on tracing the reasons for different clinical outcomes (including resistance, relapse, and toxicities) in patients treated with CAR T-cells. Grouping patients with different characteristics and comparing differences in metadata may bring more meaningful discoveries and guide further improvement of CAR T-cell therapy, such as combination therapy and engineered CAR T-cells